Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


NAD+: a metabolic knob fine-tuning inflammation during senescence

The senescence-associated secretory phenotype (SASP) is responsible for the deleterious effects of senescent cells in ageing and cancer. A new study shows that NAD+ metabolism can regulate the pro-inflammatory SASP, thereby promoting tumorigenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: NAD+ metabolism regulates the pro-inflammatory SASP and can promote tumour progression.


  1. Herranz, N. & Gil, J. J. Clin. Invest. 128, 1238–1246 (2018).

    Article  Google Scholar 

  2. Georgilis, A. et al. Cancer Cell 34, 85–102.e109 (2018).

    Article  CAS  Google Scholar 

  3. Nacarelli, T. et al. Nat. Cell Biol. (2019).

  4. Narita, M. et al. Cell 126, 503–514 (2006).

    Article  CAS  Google Scholar 

  5. Garten, A. et al. Nat. Rev. Endocrinol. 11, 535–546 (2015).

    Article  CAS  Google Scholar 

  6. Rielland, M. et al. J. Clin. Invest. 124, 2125–2135 (2014).

    Article  CAS  Google Scholar 

  7. Kaplon, J. et al. Nature 498, 109–112 (2013).

    Article  CAS  Google Scholar 

  8. Rajman, L., Chwalek, K. & Sinclair, D. A. Cell Metab. 27, 529–547 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jesús Gil.

Ethics declarations

Competing interests

J.G. owns equity in and is a consultant for Unity Biotechnology. Unity Biotechnology funds research on senolytics in the laboratory of J.G. J.G is a named inventor in a filed MRC patent related to senolytic therapies (PCT/GB2018/051437) that has been licensed to Unity Biotechnology.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Søgaard, P.P., Gil, J. NAD+: a metabolic knob fine-tuning inflammation during senescence. Nat Metab 1, 310–311 (2019).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing